Date: 2017-05-16
Type of information: Nomination
Compound: chief operating officer
Company: Lysogene (France)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 16, 2017, Lysogene announced the nomination
of Philippe Mendels-Flandre as chief operating officer. Mr. Mendels-Flandre’s arrival reinforces Lysogene’s Management Team in order to accompany its new strategic growth goals. As such, he will supervise all financial activities of the company as well as partnerships and Business Development initiatives. Mr. Mendels-Flandre will be a member of the Executive Committee. Previously, Mr. Mendels-Flandre was Shire’s – pharmaceutical group specialized in rare diseases
- EAMEA General Manager, which he joined in 2000 when the company was still called Baxter, then Baxalta. For 15 years, Mr. Mendels-Flandre held various important – strategic, marketing, manufacturing or financial - positions within the Group. Throughout his career, Mr. MendelsFlandre
developed a great multidisciplinary expertise, particularly in cross-group, international projects management. Among others, he contributed to Baxalta’s integration within Shire and to the Group’s growth in emerging countries.
Financial terms:
Latest news:
Is general: Yes
